Probiotic pill aims to stop recurrent cystitis without antibiotics
NCT ID NCT07676604
First seen Jun 30, 2026 · Last updated Jul 07, 2026 · Updated 4 times
Summary
This study tests whether a daily probiotic supplement called Colipral® can prevent repeat bladder infections (cystitis) in menopausal women aged 55–70. Participants take either the probiotic or a placebo for 12 weeks and are monitored for 24 weeks to see if they have fewer infections, need fewer antibiotics, and feel better overall. The goal is to find a safe, non-antibiotic way to manage this common condition.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Colipral® (probiotic strain Escherichia coli 5C (ECP24®))
- What this could lead to
- If effective, this probiotic could offer a non-antibiotic way to prevent recurrent cystitis in menopausal women, reducing antibiotic use and improving quality of life.
- What could go wrong
- This is a small, early-stage trial with 134 participants. The probiotic may not prove better than placebo, and individual results may vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 134 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
55 to 70 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Menopausal female patients. * Age between 55 and 70 years. * Diagnosis of recurrent cystitis: ≥2 episodes in 6 months or ≥3 episodes in 12 months, with at least 1 documented episode from urine culture in the last 12 months (if available). Exclusion Criteria: * Complicated urinary tract infections (UTIs) or major complicating factors, including relevant anatomical abnormalities, catheterization, active calculosis, or significant immunosuppression. * Hormone replacement therapy (HRT) that has been ongoing or discontinued for less than 6 months. * Pyelonephritis within the past 6 months. * Ongoing continuous antibiotic prophylactic therapy (or inability to suspend it). * Chronic inflammatory bowel diseases (ulcerative colitis or Crohn's disease). * Allergy to the probiotic or its excipients.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Recurrent cystitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.